French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)
Recruiting · NCT06287749 · Observational (researchers observe without assigning treatment) · Lead sponsor: University Hospital, Montpellier
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The overall objective of this GUIDE.MRD consortium is to confirm that ctDNA detected after curative intended treatment for PDAC is a marker of residual disease and for risk-of-recurrence, and applicable in clinical practice. Primary objective To confirm that ctDNA analyses performed after PDAC treatment can identify patients with a high risk-of-recurrence. Specifically, the investigators want to determine the association between disease-free survival (DFS) and ctDNA detection status after 1. curative-intended surgery and 2. adjuvant chemotherapy. FRENCH.MRD.PDAC is the French study of the european GUIDE.MRD project
Who can take part
Inclusion criteria
- Pancreatic ductal adenocarcinoma, according to the assessment of the MDT.
- Age 18 years or older.
- Scheduled for curative intent surgical resection.
Exclusion criteria
- Hereditary pancreatic cancer.
- Verified distant metastases.
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study.
- Other cancers (excluding prior pancreatic cancer or skin cancer other than melanoma) within 3 years from eligibility screening.
- Pregnant or nursing woman, or in childbearing age and not willing to use contraception
- Adult subject to a legal protection
- Not covered by Health insurance
- Patient unable to understand and sign written informed consent.
Where it is running
1 location listed.
- CHU de Montpellier - Montpellier, Hérault, France